Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Prior studies have noted that inhibitors of mitogen-activated protein kinase (MAPK) kinase 1/2 (MEK1/2) enhanced geldanamycin lethality in malignant hematopoietic cells by promoting mitochondrial dysfunction. The present studies focused on defining the mechanism(s) by which these agents altered survival in carcinoma cells. MEK1/2 inhibitors [PD184352; AZD6244 (ARRY-142886)] interacted in a synergistic manner with geldanamycins [17-allylamino-17-demethoxygeldanamycin (17AAG) and 17-dimethylaminoethylamino-17-demethoxy-geldanamycin] to kill hepatoma and pancreatic carcinoma cells that correlated with inactivation of extracellular signal-regulated kinase 1/2 and AKT and with activation of p38 MAPK; p38 MAPK activation was reactive oxygen species dependent. Treatment of cells with MEK1/2 inhibitors and 17AAG reduced expression of c-FLIP-s that was mechanistically connected to loss of MEK1/2 and AKT function; inhibition of caspase-8 or overexpression of c-FLIP-s abolished cell killing by MEK1/2 inhibitors and 17AAG. Treatment of cells with MEK1/2 inhibitors and 17AAG caused a p38 MAPK-dependent plasma membrane clustering of CD95 without altering the levels or cleavage of FAS ligand. In parallel, treatment of cells with MEK1/2 inhibitors and 17AAG caused a p38 MAPK-dependent association of caspase-8 with CD95. Inhibition of p38 MAPK or knockdown of BID, FAS-associated death domain, or CD95 expression suppressed MEK1/2 inhibitor and 17AAG lethality. Similar correlative data were obtained using a xenograft flank tumor model system. Our data show that treatment of tumor cells with MEK1/2 inhibitors and 17AAG induces activation of the extrinsic pathway and that suppression of c-FLIP-s expression is [Mol Cancer Ther 2008;7(9):2633-48].
Park
Margaret A
MA
Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, 401 College Street, Massey Cancer Center, Box 980035, Richmond, VA 23298-0035, USA.
Zhang
Guo
G
Mitchell
Clint
C
Rahmani
Mohamed
M
Hamed
Hossein
H
Hagan
Michael P
MP
Yacoub
Adly
A
Curiel
David T
DT
Fisher
Paul B
PB
Grant
Steven
S
Dent
Paul
P
D000818:Animals; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D016227:Benzoquinones / Q000494:pharmacology*; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000201:enzymology / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D004357:Drug Synergism; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000201:enzymology / Q000473:pathology*; D006801:Humans; D047029:Lactams, Macrocyclic / Q000494:pharmacology*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D051379:Mice; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays; D019014:fas Receptor / Q000378:metabolism*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D051017:Apoptosis Regulatory Proteins; D016227:Benzoquinones; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; D047029:Lactams, Macrocyclic; D047428:Protein Kinase Inhibitors; D017382:Reactive Oxygen Species; D019014:fas Receptor; C112765:tanespimycin; D051057:Proto-Oncogene Proteins c-akt; D048051:p38 Mitogen-Activated Protein Kinases; D020929:Mitogen-Activated Protein Kinase Kinases
J Biol Chem. 2003 May 23;278(21):18811-6
12646560
J Biol Chem. 2005 Oct 21;280(42):35217-27
16109713
Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16
14613031
Clin Cancer Res. 2007 Aug 15;13(16):4934-42
17652623
Nature. 2003 Sep 25;425(6956):407-10
14508491
Gut. 2003 May;52(5):706-12
12692057
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Mol Cancer Ther. 2007 Mar;6(3):789-801
17363476
Br J Surg. 1998 Oct;85(10):1319-31
9782009
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47
16609040
Mol Cell Biol. 2003 May;23(9):3052-66
12697808
J Antibiot (Tokyo). 1970 Sep;23(9):442-7
5459626
Expert Opin Ther Targets. 2006 Feb;10(1):27-35
16441226
Cancer. 2003 Apr 15;97(8):1929-40
12673720
Expert Opin Emerg Drugs. 2002 Oct;7(2):277-88
15989551
Mol Cell Biol. 2004 Dec;24(23):10352-65
15542843
Clin Cancer Res. 2006 Jan 15;12(2):584-90
16428504
Arch Biochem Biophys. 2007 May 15;461(2):275-86
17382893
Cancer Biol Ther. 2005 Nov;4(11):1275-84
16319524
Cell Cycle. 2007 Jun 1;6(11):1393-402
17525527
Oncogene. 2003 Sep 1;22(37):5885-96
12947395
J Biol Chem. 1997 Feb 14;272(7):4013-20
9020108
Oncogene. 2005 Feb 17;24(8):1477-80
15608678
Mol Cancer Ther. 2007 Feb;6(2):618-32
17308059
Clin Cancer Res. 2005 May 1;11(9):3385-91
15867239
J Cell Physiol. 2003 May;195(2):290-7
12652655
Mol Biol Cell. 2001 Sep;12(9):2629-45
11553704
Mol Cancer Ther. 2007 Jan;6(1):138-46
17237274
J Biol Chem. 2004 Feb 13;279(7):5821-8
14660582
Cell Death Differ. 2004 Oct;11(10):1084-91
15243584
Mol Cancer Ther. 2004 Aug;3(8):1021-30
15299085
Int J Cancer. 2007 Sep 15;121(6):1227-37
17534891
J Clin Oncol. 2005 Aug 10;23(23):5281-93
16009947
Hepatology. 2004 Oct;40(4):961-71
15382121
Blood. 2003 Jul 1;102(1):269-75
12623837
Nat Cell Biol. 2003 Jul;5(7):647-54
12792650
Mol Cancer Ther. 2007 Aug;6(8):2209-19
17699718
J Clin Oncol. 2005 Mar 20;23(9):1885-93
15774780
Cancer Res. 2001 Mar 1;61(5):1799-804
11280726
World J Gastroenterol. 2007 Apr 28;13(16):2271-82
17511024
Hepatology. 2001 Nov;34(5):906-17
11679961
J Clin Oncol. 2004 Nov 15;22(22):4456-62
15483017
Biochem Pharmacol. 2007 May 15;73(10):1665-75
17303086
Cancer Cell. 2003 Mar;3(3):213-7
12676580
Vitam Horm. 2004;67:189-206
15110178
J Clin Oncol. 2005 Jun 20;23(18):4152-61
15961763
Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3819-23
7731990
Curr Opin Pharmacol. 2005 Aug;5(4):350-6
15955734